HYBRID EVENT: You can participate in person at Renaissance London Heathrow Hotel, UK or Virtually from your home or work.

Dr. Jonathan Alvin Wiryaputra

 

Dr. Jonathan Alvin Wiryaputra

National Cardiovascular Center Harapan Kita Hospital, Indonesia

Abstract Title:Stem Cell Therapy in Post-CABG Patients with Cardio-Diabetes: A Potential Strategy for Cardiac Repair and Recovery

Biography:

Jonathan Alvin Wiryaputra is a medical doctor from Airlangga University with extensive experience in cardiovascular thoracic surgery. He has undertaken several elective programs in Japan and Taiwan, gaining valuable insights into advanced medical practices. Throughout his career, Dr. Jonathan has been involved in numerous multidisciplinary research projects, both nationally and internationally, collaborating with leading referral hospitals across Indonesia. His current focus lies in thoracic cardiovascular surgery, particularly its practical implementation in clinical settings. Dr. Jonathan continues to contribute to the advancement of surgical techniques and patient care in Indonesia’s healthcare landscape.

Research Interest:

National Cardiovascular Center Harapan Kita Hospital, Indonesia
Coronary artery bypass grafting (CABG) is a common treatment for patients with severe coronary artery disease (CAD), frequently complicated by comorbid conditions such as cardio-diabetes. Diabetes mellitus exacerbates vascular dysfunction, impedes tissue repair, and increases the risk of post-surgical complications, including poor graft patency, impaired myocardial recovery, and heart failure. Stem cell therapy has emerged as a promising adjunct to conventional CABG, offering potential benefits in repairing damaged myocardial tissue, enhancing angiogenesis, and improving overall cardiac function in this high-risk patient population. Mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and cardiac progenitor cells (CPCs) have been explored for their regenerative potential in post-CABG patients. In patients with cardio-diabetes, where chronic hyperglycemia exacerbates myocardial injury and fibrosis, stem cells may improve endothelial function, reduce inflammation, and stimulate tissue repair. Preclinical and clinical studies suggest that stem cell therapy can enhance left ventricular ejection fraction (LVEF), promote myocardial regeneration, and potentially improve long-term graft survival. Despite these promising results, significant challenges remain, including optimizing cell delivery methods, addressing patient-specific factors such as glycemic control, and ensuring long-term safety and efficacy. This review highlights the current evidence supporting the role of stem cell therapy in post-CABG patients with cardio-diabetes and emphasizes the need for further randomized controlled trials to define treatment protocols, evaluate clinical outcomes, and establish the optimal use of stem cell therapies in this patient cohort.